BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 30, 2022
Data Byte

Assessing an expanse of ALS targets 

Restoring neurotransmission may be the key to slowing fatal disease
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

Three late-stage readouts this year and multiple mechanisms in the clinic could lift the lid on ALS treatments
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The idea that neuroinflammation drives ALS will get its most rigorous test to date with the Healey ALS platform trial.
BioCentury | May 1, 2019
Translation in Brief

White matter matters in Alzheimer’s

Single-cell transcriptomes reveal myelin role, cell type-specific markers in Alzheimer’s
BioCentury | Sep 28, 2018
Tools & Techniques

Deconstructing tox in immuno-oncology

Reverse translating better preclinical models of cancer immunotherapy tox
BioCentury | Jun 13, 2013
Distillery Therapeutics

Indication: Infectious disease

BioCentury | May 16, 2013
Cover Story

Eritoran insight for influenza treatment

BioCentury | Mar 11, 2013
Clinical News

Cenicriviroc: Additional Phase IIb data

BioCentury | Jan 21, 2010
Distillery Therapeutics

Indication: Infectious disease

Items per page:
1 - 10 of 24